| Literature DB >> 31432648 |
Elisabetta Stenner1, Luca Giovannella2, Giorgia Raffaelli3, Giorgio Delbello4, Maurizio Ruscio1, Roberto Verna5,6.
Abstract
Entities:
Mesh:
Substances:
Year: 2020 PMID: 31432648 PMCID: PMC6713650 DOI: 10.3343/alm.2020.40.1.92
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Biochemical parameters during the four-month training period (T1–T5), immediately after the Lapland Extreme Challenge (T6), and a few months after the Lapland Extreme Challenge (T7–T9)
| Analyte | Reference range | RCV (%) | T1–T5 mean ± SD (CV%) | T6 | T7–T9 mean ± SD (CV%) |
|---|---|---|---|---|---|
| Creatine kinase (µKat/L)* | 0.42–3.31 | 39 | 6.66 ± 5.49 (82) | 12.39 | 5.25 ± 2.23 (42) |
| Lactate dehydrogenase (µKat/L)* | < 4.17 | 23 | 3.40 ± 1.12 (33) | 4.27 | 2.95 ± 0.13 (5) |
| Myoglobin (nmol/L)† | < 4.00 | 43 | 1.66 ± 0.17 (12) | 2.40 | 1.83 ± 0.34 (18) |
| Sodium (mmol/L)* | 135–145 | 5 | 140 ± 1 (0.8) | 140 | 140 ± 1 (0.7) |
| Potassium (mmol/L)* | 3.50–5.10 | 8 | 4.63 ± 0.49 (11) | 5.57 | 4.5 ± 0.5 (11) |
| Phosphorus (mmol/L)* | 0.81–1.45 | 15 | 1.16 ± 0.07 (6) | 1.16 | 1.13 ± 0.01 (0.3) |
| Calcium (mmol/L)* | 2.12–2.62 | 5 | 2.31 ± 0.11 (5) | 2.21 | 2.31 ± 0.13 (6) |
| Magnesium (mmol/L)* | 0.73–1.05 | 8 | 0.82 ± 0.02 (2) | 0.90 | 0.86 ± 0.03 (4) |
| Enzymatic creatinine (µmol/L)* | 44–115 | 12 | 86 ± 2 (3) | 103 | 91 ± 4 (5) |
| Cystatin C (mg/L)‡ | 0.20–0.62 | NA | 0.25 ± 0.02 (7) | 0.25 | 0.27 ± 0.03 (10) |
| Neutrophil gelatinase-associated lipocalin (µg/L)‡ | ≤ 60 | NA | 20 ± 0 (0) | 20 | 20 ± 10 (34) |
| Bone alkaline phosphatase (µg/L)† | 3.70–21.00 | 20 | 9.92 ± 0.96 (10) | 7.1 | 10.30 ± 0.15 (1.5) |
| Carboxy-terminal collagen crosslinks (ng/L)§ | 120–750 | 30 | 530 ± 60 (11) | 390 | 470 ± 30 (6) |
| 25-hydroxy-vitamin D (nmol/L)∥ | 75–125 | NA | 82 ± 5 (6) | 78 | 67 ± 12 (20) |
| Osteocalcin (µg/L)∥ | 4.60–65.40 | 31 | 17.20 ± 1.90 (11) | 9.2 | 17.10 ± 1.40 (8) |
| Parathyroid hormone (ng/L)† | 11–88 | 55 | 36 ± 10 (29) | 32 | 51 ± 22 (42) |
| Cortisol (nmol/L)† | 185–624 | 31 | 417 ± 77 (18) | 178 | 452 ± 97 (21) |
*Analytes were tested using the AU5800 analyzer (Beckman Coulter, Fullerton, CA, USA); †Analytes were tested using the UniCel DXI800 system (Beckman Coulter); ‡Analytes were tested using the CKD Array II, Chemiluminescence Biochip Array Technology (Evidence Series; Randox Laboratories Ltd., Crumlin, UK); §Analyte was tested using the Alisei system (Omnia Diagnostic, Cranbury, NJ, USA); ∥Analytes were tested using the Liaison XL analyzer (Diasorin, Saluggia, TO, Italy).
Abbreviations: RCV, reference change value; NA, not available.
Fig. 1Changes in biochemical parameters during the four-month training period (T1–T5), immediately after the Lapland Extreme Challenge (T6), and a few months after the Lapland Extreme Challenge (T7–T9): (A) Cortisol, (B) bone alkaline phosphatase, and (C) osteocalcin.